Avelumab with axitinib for untreated advanced renal cell carcinoma

Avelumab (Bavencio, Merck Serono) with axitinib is indicated for 'the first-line treatment of adult patients with advanced renal cell carcinoma'.

The dosage schedule is available in the summary of product characteristics for avelumab.

The list price for avelumab is £768.00 for a 20 mg per 1 ml vial (excluding VAT; BNF online, accessed April 2025). The company has a commercial arrangement. This makes avelumab available to the NHS with a discount. The size of the discount is commercial in confidence.

The list price for axitinib is £3,517.00 for a 56 pack of 5‑mg tablets (excluding VAT; BNF online, accessed November 2025). The list price varies by pack size or dose. Costs may vary in different settings because of negotiated procurement discounts.

For information, the Carbon Reduction Plan for UK carbon emissions is published on Merck Serono's webpage on Sustainability